Home Huihe Medical Completes Hundreds of Millions RMB Series D Financing and Files IPO Prospectus

Huihe Medical Completes Hundreds of Millions RMB Series D Financing and Files IPO Prospectus

Jan 03, 2026 17:22 CST Updated 17:22
H&H Healthcare

R&D and Producer of Interventional Medical Devices for Heart Disease

图片
Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Follow


Source: HuiHe Healthcare

Recently,Shanghai Huihe Healthcare Technology Co., Ltd. (hereinafter referred to as "HuiHe Healthcare") announced the completion of its D-round financing.This round of financing was strategically led by Taiping Healthcare Fund, with follow-up investment from the old shareholder, Suzhou Sherpa Two Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Sherpa").This is another significant milestone for HuiHe Healthcare since the completion of its C+ round of financing in 2022.Marks the company's innovative strength in the field of interventional treatment for structural heart disease being highly recognized by the capital market.

In recent years, insurance funds have become an important driving force for the development of the medical and health industry. As a typical representative of "patient capital," insurance funds possess unique advantages such as long-term stability, consistency, and cross-cycle allocation, which align closely with the long-cycle and high-investment characteristics of the medical and health industry. Meanwhile, as the payer in the medical and health industry, insurance has a natural connection with innovative medical device companies. By reasonably building a complete health management ecosystem that integrates "clients + payers + demand side + resource providers," the insurance sector can achieve deep synergy with the medical industry.

HuiHe Healthcare has gained the favor of Taiping Medical Health Fund under Taiping Insurance due to its unique competitive advantages and significant growth potential. The company holds industry-leading positions in delivery systems, precision manufacturing, simulation modeling, and automated production, with several independently developed, world-leading commercialized products in the cardiovascular intervention field.The core product K-Clip® Transcatheter Tricuspid Valve Repair System, a global first, replicates classic surgical procedures to repair tricuspid regurgitation through minimally invasive surgery, and was approved for marketing by the National Medical Products Administration (NMPA) in March 2025.Large-scale commercial applications have currently been carried out.

Taiping Healthcare Fund: Taiping Healthcare Fund always adheres to research-driven investment practices, continuously focusing on the most innovative and competitively promising products globally.HuiHe Healthcare, with its original innovative interventional medical device K-Clip®, has pioneered a new surgical technique for tricuspid annuloplasty repair. In the future, it is expected to become a commercially viable tricuspid annuloplasty reduction and repair product on a global scale.Looking forward to HuiHe Healthcare continuously iterating and developing with "Annuloplasty Technology" and the concept of "One Valve, Dual Repair," serving patients worldwide.

Cai Da, Founding Managing Partner of Sherpa InvestmentQing: The completion of this round of financing will provide HuiHe Healthcare with sufficient financial support, rich insurance channels, and medical institution resources for the commercialization of its products.Accelerate the promotion and application of products such as K-Clip® in the Chinese and overseas markets, laying a solid foundation for the company's performance growth.Sherpa continues to have a positive outlook on HuiHe Healthcare's R&D capabilities and commercialization prospects, and has firmly made multiple follow-up investments since the initial investment.

Chairman of HuiHe Healthcare, Lin Lin: HuiHe Healthcare Completes Series D Financing, a Significant Layout by Taiping Healthcare Fund in the Field of Structural Heart Disease Interventional Treatment. It also serves as a vivid practice of insurance capital supporting the development of new productive forces and promoting technological self-reliance and strength. This will inject strong momentum into the company's commercialization process and global development. Meanwhile, we would like to thank Sherpa for their long-term firm support and recognition of HuiHe Healthcare.HuiHe Healthcare will continue to make breakthroughs and innovations in the field of cardiovascular interventions, providing patients with less invasive and safer treatment options, as well as offering doctors simpler and more controllable surgical tools.Contribute Chinese wisdom and solutions to the global healthcare cause.


图片

About Shanghai Huihe Healthcare Technology Co., Ltd.


Shanghai Huihe Healthcare Technology Co., Ltd. (referred to as "HuiHe Healthcare") is a high-tech enterprise focused on the research, development, production, and commercialization of cardiovascular interventional medical devices, with its headquarters located in Songjiang District, Shanghai. Driven by the principles of "combining medical expertise with engineering" and "original innovation," HuiHe Healthcare is committed to promoting China-produced high-end medical devices globally.


About Taiping Medical Health Fund


Taiping Healthcare Fund was established in 2021, with a registered fund size of 10 billion yuan, and is managed by Taiping Innovation Investment Management Co., Ltd. The fund focuses on the fields of biopharmaceuticals, medical devices and diagnostics, medical services, biotechnology, and healthcare informatization, extending to related areas such as health technology and health consumption. It is committed to building a "Insurance + Medical Care and Elderly Care" ecosystem with Taiping characteristics.


Regarding Suzhou Sherpa Phase II Equity Investment Partnership (Limited Partnership)


Sherpa Investment is a fund management company focused on early-stage and growth-stage healthcare investments. Adhering to the philosophy of "investing early, investing in innovation, and investing accurately," it leverages long-term accumulated industry insights and advantageous resources to address unmet critical clinical needs in major disease areas. The firm builds its investment portfolio around sectors such as gene technology and its applications, biopharmaceuticals, medical devices and diagnostics, and digital healthcare. It expands along the depth of the industry and its upstream and downstream segments, forming enterprise synergies, with investment presence in both China and the United States.





END
 



More exciting content

Welcome to follow WeChat Video Channel

Instrument Family
Image
Related Reading

Image
Tap for more!








China-Made "High-Priced" Products Also Win Bids: Turning Point for Centralized Procurement of High-End Medical Devices Arrives

Selected for the National Museum: Neusoft, Mindray, MGI...

Just now, the "King of Hemodialysis" Chief Medical Officer takes office

Paradigm Elevation: HeartFlow Medical's Heart Failure Management Revolution

United Imaging-backed, "China's First and Only" Secures 1 Billion in Financing

Top Ten Overseas Medical Device News in 2025

Serving 4 Billion Worldwide: CT "Heart" Makes Significant Layout in Hainan

China's First Nuclear Medicine Demonstration Base Inaugurated in Suzhou

A-share Medical Device Leader: Fined Over 14 Million Yuan

Johnson & Johnson Medical Technology Bets on Three Major Tracks


Image

BusinessBusiness cooperation email: qxzj@landianyiliao.com


Image



Image
Image